United States

Agenus Inc (AGEN.OQ)

AGEN.OQ on NASDAQ Stock Exchange Capital Market

24 Mar 2017
Change (% chg)

$-0.04 (-1.02%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

QVT Financial reports 5.08 pct passive stake in Agenus
Friday, 3 Feb 2017 05:03pm EST 

Agenus Inc :QVT Financial Lp reports a 5.08 percent passive stake in Agenus Inc as of January 24, 2017 - sec filing.  Full Article

Agenus files for offering of up to 157,513 shares by selling stockholder
Friday, 20 Jan 2017 04:21pm EST 

Agenus Inc :Files for offering of up to 157,513 shares of co's common stock by the selling stockholder - SEC filing.  Full Article

Agenus Q2 loss per share $0.33
Thursday, 28 Jul 2016 08:50am EDT 

Agenus Inc : Qtrly revenue $6.6 million versus $6.4 million . Agenus reports second quarter 2016 financial results and operational progress . Q2 loss per share $0.33 . Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S .Q2 revenue view $5.1 million -- Thomson Reuters I/B/E/S.  Full Article

Agenus' chief financial officer, C.Evan Ballantyne to resign
Tuesday, 19 Jul 2016 08:51am EDT 

Agenus Inc : On july 14, 2016, C. Evan Ballantyne, chief financial officer informed agenus of his intention to resign - sec filing .Christin Klaskin, Agenus' VP, finance and principal accounting officer, will retain her roles, assume role of principal financial officer.  Full Article

Agenus Inc starts phase 1/2 clinical trial of anti-GITR agonist antibody
Wednesday, 22 Jun 2016 08:50am EDT 

Agenus Inc : Expect to initiate additional clinical studies with antibodies and immuno-oncology leads from comprehensive pipeline in next twelve months .Agenus announces commencement of phase 1/2 clinical trial of anti-GITR checkpoint antibody INCAGN1876 in patients with solid tumors.  Full Article

Agenus Inc acquires PhosImmune
Wednesday, 23 Dec 2015 08:00am EST 

Agenus Inc:Acquired privately-held PhosImmune Inc., a company that has discovered an entirely new portfolio of cancer neoantigens.The acquisition provides Agenus the ability to accelerate the development of new cancer vaccines and other single agent immuno-oncology approaches, as well as combination therapies.Under the terms of the agreement, Agenus paid PhosImmune's equity holders an upfront payment of $2.5 million in cash and $7.4 million in shares of Agenus common stock at closing.Additional payments of up to $35 million in cash and/or stock at Agenus' election are payable upon the achievement of certain.  Full Article

Agenus to acquire antibody manufacturing capability and capabilities from XOMA
Thursday, 5 Nov 2015 04:00pm EST 

Agenus Inc:To acquire biologics manufacturing facility and capabilities from XOMA.Acquires rights to Selexis cell line development technology.Purchases an exclusive license to a Phage Display library from Iontas.Under the terms of the agreement with XOMA, Agenus will pay at closing $5.0 million in cash and up to $1.0 million in common stock.  Full Article

Agenus Inc acquires novel antibodies to immuno-oncology Target CEACAM1
Monday, 20 Jul 2015 07:00am EDT 

Agenus Inc:Has acquired rights to antibodies targeting Carcinoembryonic Antigen Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein expressed on T cell and NK cell lymphocytes from Diatheva s.r.l.Antibodies targeting CEACAM1 are thought to have the potential to effectively treat cancer alone or in combination with other checkpoint modulator antibodies, including those in Agenus` development pipeline.Under license agreement, Agenus receives exclusive, worldwide rights for development and commercialization of CEACAM1 antibodies from Diatheva.Agenus is responsible for certain upfront, early development, clinical trial and regulatory milestone payments for successful development of CEACAM1 antibodies totaling as much as $44 mln.Diatheva is also eligible to receive additional sales milestones and royalties.  Full Article

Agenus appoints C. Evan Ballantyne as chief financial officer
Wednesday, 17 Jun 2015 07:00am EDT 

Agenus Inc:Appoints C. Evan Ballantyne as chief financial officer.  Full Article

Merck extends immuno-oncology collaboration with Agenus Inc
Wednesday, 3 Jun 2015 07:00am EDT 

Agenus Inc:Says discovery phase has been extended to April 2016.Merck will be responsible for the further development and commercialization of candidates generated under the collaboration.Agenus - Co will discover and optimize fully human antibodies against two undisclosed merck checkpoint targets using retrocyte display platform.  Full Article

More From Around the Web

BRIEF-Incyte and Agenus amend collaboration agreement

* Incyte Corp - amended agreement converts ongoing GITR and ox40 antibody programs from co-funded development and profit-sharing arrangements to royalty-bearing programs